Search PubMed⌕ Search

Biomedical subjects

K Jarczok

Publications and source records attributed to K Jarczok.

At least 37 records · Page 2Linked to original sources
PubMed1984

Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML.

In a prospective study 100 AML cases were randomized in two groups and underwent remission induction treatment in 4 departments with "Ara-C c. inf. from the first to the eight day plus Adr. from the first to the third day" or "Ara-C + 6-TG + Adr., 6 + 6 + 2 days". The CR patients were divided into two subgroups. Subgroup A obtained maintenance therapy with 5 day course of Ara-C s.c. in addition to 6-TG, Vincristine plus Prednisone and Adriamycin sequentially, with each cycle repeated at 6 week intervals. Subgroup B obtained the calf thymus extract (TFX-Polfa) between the cycles additionally. The current results of remission induction treatment are similar to "8 + 3" and "6 + 6" regimens as measured by the CR rate (45% and 44%), survival curves (survival after 24 months - 23% and 28% respectively) and relapse rates (3.5%/pt.mo.obs. and 5.3%/pt.mo.obs.). It is still too early to evaluate the efficacy of this maintenance treatment, because the programme is still open to patient entries. At present 13 patients received maintenance regimen A and 12 patients received maintenance regimen B, with an average survival being equal to 14 and 13.5 months respectively.

Adult↗
PubMed1984

Application of series of monoclonal antibodies against human white cell differentiation antigens and the common ALL antigen in the characterization of leukemia cells.

The specificity and the clinical usefulness of the hybridoma derived monoclonal antibodies raised against the differentiation antigens of granulocytes (VIM-D5, VIM-C6), monocytes (VIM-D2), B lymphocytes (VIB-C5, VIC-Y1), erythrocytes (VIE-G4) and CALLA (VIL-A1) was studied in leukemic cells isolated from peripheral blood and bone marrow of 41 adults with acute leukemia by using indirect fluorescence method. The VIL-A1 positivity was observed in 4/9 of ALL and in none of myeloid leukemia. It was accompanied in 3/4 of cases by VIB-C5 positivity and in one case by VIE-G4 positivity. It is important that 2 out 3 unclassifiable cases (PAS-) could be diagnosed as common ALL due to their VIL-A1 positivity. VIM-D5 like VIM-C6 reacted specifially with granulocytic cells only and gave positive results in 20/30 of acute myeloid leukemias. When classified according to the FAB scheme, the proportion of VIM-D5 + patients rose from M1 toward more mature subtypes, including M4/5. It allowed to identify as AML 2/6 of unclassifiable-Mo leukemias, VIC-Y1 appeared to be helpful in characterization of B cell malignancies and of myelomonocytic leukemias. It is concluded that the monoclonal antibodies of VI series are specific and allow a more precise definition of leukemia, thus helping in optimalization of treatment.

Antibodies, Monoclonal↗
PubMed1984

Electrophoretic mobility of blood lymphocytes stored at -196 degrees.

To determine the influence of low temperature (-196 degrees C) during preservation upon the electrophoretic mobility (EM) of lymphocytes ten healthy donors were examined. Lymphocytes were isolated from venous blood by Ficoll-Uropolinum (Polfa) density gradient centrifugation and iron powder technique was used to eliminate macrophages. EM of lymphocytes was analyzed on Parmoquant 2 computer system (Carl-Zeiss, Jena) before and ten days after cryopreservation. There was no significant difference between the mean EM before freezing (1.046 um.sec-1.v-1.cm) and after it (1.034 um.sec.-1v-1 cm). No significant changes in histograms showing slow (lymphocytes B) and fast (lymphocytes T) fractions were observed. It indicates, that cryopreservation does not change EM of lymphocytes and thus can be used in situations, when immediate examination cannot be done.

Adult↗
PubMed1984

Parallel examination of receptors of malignant lymphoma cells using combined tests with mouse erythrocytes and monoclonal VIB-C5 antibody or polyvalent serum against human immunoglobulins.

This report presents the results of studies on two membrane markers of lymphocytes isolated from patients with non-Hodgkin's lymphoma. The combined methods were applied allowing for a simultaneous testing of: a) presence of the membrane receptor for mouse erythrocytes (Em) and membrane immunoglobulins (SmIg) or b) presence of the receptor for mouse erythrocytes and antigen binding monoclonal VIB-C5 antibody (VIB). In 12 patients with the low grade malignant lymphoma, up to 50% of lymphocytes possessed both receptor for mouse erythrocytes as well as membrane immunoglobulins and higher frequency of occurrence of Em+ cells were associated mainly with a high percentage of SmIg-- cells. In 9 patients with low grade malignant lymphoma, 24% of cells were observed to possess Em receptor and antigen detectable with VIB antibody, 34-70% of cells were Em-VIB-lymphocytes and 13-54% were Em-VIB+ cells. The results obtained have revealed that the application of monoclonal antibody renders possible the diagnosis of lymphoma and may be of particular value in the cases with weak expression of receptor for mouse erythrocytes.

Animals↗
PubMed1983

Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.

51 patients (mean age 40, range 17-71) with previously untreated AML (25% of M4-6 FAB type) were given Ara-C subcutaneously 100 mg/m2 every 12 h for 7 days and DNR 45 mg/m2 on days 1-3 i.v. for inducing remission. After 52 days 49% of patients on an average reached CR. The complete responders were given a 5 day treatment pulses monthly until relapse, which consisted of Ara-C s.c. plus one of the following drugs added in cyclic rotation: 6-TG, cyclophosphamide, CCNU or DNR. After 2 years the intervals between cycles were prolonged step by step. The mean/median of CR duration equals 26/19 months and of the survival of complete responders 32.9/27 months. The relapse rate and the CNS relapse rate equaled 1.9% and 0.36% per patient/month of observation. T and B cell depletion was observed during maintenance. The results indicate that the subcutaneous route of administering Ara-C is effective during the induction of remission.

Adolescent↗
PubMed1981

Hemophilia A in a female with gonadal dysgenesis and XX karyotype.

The authors present a case of a coincidence of two very rare diseases in a female--hemophilia A and gonadal dysgenesis; both may be caused by chromosomal and genetic abnormalities. The girl, aged 22, presented severe hemophilia with excessive haematoma after bruising and recurrent hemarthroses, had undeveloped breasts and very hypoplastic internal genital organs. Laboratory tests revealed factor VIII: C - 1%, VIII R: AG - 160%, VIII:WF - 111%, 46, XX karyotype, elevated LH in urine - 25 IU/l. This coincidence had a beneficial effect since there was no menorrhagia.

Adult↗
PubMed1981

Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases.

In 4 adults with malignant lymphoma and in 3 cases of acute lymphoblastic leukemia the acid phosphatase activity in lymphocytes during the consecutive cycles of polychemotherapy was examined paralelly with the estimation of the receptors for sheep erythrocytes. Depression of the enzymatic reaction was observed immediately after the onset of the cytostatic treatment, its normalization between the cycles and after the full remission was reached. A remarkable and lasting decrease of the phosphatase positive lymphocytes and a change in the expression of the enzymatic reaction was noticed in the course of L-asparaginase administration. The presented investigations are the continuation of the authors' earlier studies on the positive correlation between the rosette test with neuraminidase treated sheep erythrocytes and the acid phosphatase activity in lymphoproliferative diseases.

Acid Phosphatase↗